Results 121 to 130 of about 839,337 (241)

Sex Differences in Response to Viral Vector Vaccines—Implications for Future Vaccine Design

Immunological Reviews, Volume 338, Issue 1, March 2026.
ABSTRACT Vaccination represents one of the most impactful public health achievements, preventing 3.5 to 5 million deaths annually according to estimates of the World Health Organization. Yet, recent outbreaks of emerging and reemerging infectious diseases highlight the need for rapid and strategic vaccine development using vaccine platforms ...
Ilka Grewe, Tamara Zoran, Marylyn Martina Addo   +2 more
wiley   +1 more source

Safety and immunogenicity of an mRNA-1273 vaccine booster in adolescents

Human Vaccines & Immunotherapeutics
Safety, immunogenicity, and effectiveness of an mRNA-1273 50-μg booster were evaluated in adolescents (12–17 years), with and without pre-booster SARS-CoV-2 infection.
Amparo L. Figueroa, Kashif Ali, Gary Berman, Wenqin Xu, Weiping Deng, Bethany Girard, Anne Yeakey, Karen Slobod, Jacqueline Miller, Rituparna Das, Frances Priddy   +10 more
doaj   +1 more source

Real-world effectiveness of the mRNA-1273 vaccine against COVID-19: Interim results from a prospective observational cohort study

The Lancet Regional Health. Americas, 2022
Summary: Background: Phase 3 trials found mRNA-1273 was highly effective in preventing COVID-19. We conducted a prospective cohort study at Kaiser Permanente Southern California (KPSC) to determine the real-world vaccine effectiveness (VE) of mRNA-1273 ...
Katia J. Bruxvoort, Lina S. Sy, Lei Qian, Bradley K. Ackerson, Yi Luo, Gina S. Lee, Yun Tian, Ana Florea, Harpreet S. Takhar, Julia E. Tubert, Carla A. Talarico, Hung Fu Tseng   +11 more
doaj   +1 more source

Risk factors for SARS-CoV-2 infection after primary vaccination with ChAdOx1 nCoV-19 or BNT1262b2 and after booster vaccination with BNT1262b2 or mRNA-1273: a population-based cohort study (COVIDENCE UK) [PDF]

, 2022
Giulia Vivaldi, David A. Jolliffe, Hayley Holt, Florence Tydeman, Mohammad Talaei, Gwyneth A. Davies, Ronan A Lyons, Chris Griffiths, Frank Kee, Aziz Sheikh, Seif O. Shaheen, Adrian R. Martineau   +11 more
openalex   +1 more source

Comparative analysis of the characteristics and trends of adverse drug reaction reports from patients in Japan and the Japanese Adverse Drug Event Report database

British Journal of Clinical Pharmacology, Volume 92, Issue 2, Page 515-524, February 2026.
Aims Spontaneous reporting of adverse drug reactions (ADR) after a product has reached the market is essential for drug safety. This study analysed patient ADR reports and compared them with reports from the Japanese Adverse Drug Event Report (JADER) database to identify differences and trends.
Masami Tsuchiya, Ryohkan Funakoshi, Koichi Masuyama, Nariyasu Mano, Satoko Hori, Taku Obara   +5 more
wiley   +1 more source

Humoral and cellular immune response and safety of two-dose SARS-CoV-2 mRNA-1273 vaccine in solid organ transplant recipients

American Journal of Transplantation, 2021
Solid organ transplant recipients are at high risk of severe disease from COVID‐19. We assessed the immunogenicity of mRNA‐1273 vaccine using a combination of antibody testing, surrogate neutralization assays, and T cell assays.
Victoria G Hall, V. Ferreira, M. Ierullo, T. Ku, T. Marinelli, B. Majchrzak-Kita, Anila Yousuf, V. Kulasingam, A. Humar, Deepali Kumar   +9 more
semanticscholar   +1 more source

Determinants of antibody responses to two doses of ChAdOx1 nCoV-19 or BNT162b2 and a subsequent booster dose of BNT162b2 or mRNA-1273: population-based cohort study (COVIDENCE UK) [PDF]

, 2022
David A. Jolliffe, Sian Faustini, Hayley Holt, Natalia Perdek, Sheena Maltby, Mohammad Talaei, Matthew Greenig, Giulia Vivaldi, Florence Tydeman, Jane Symons, Gwyneth A. Davies, Ronan A Lyons, Chris Griffiths, Frank Kee, Aziz Sheikh, Seif O. Shaheen, Alex Richter, Adrian R. Martineau   +17 more
openalex   +1 more source

Optimized ACE2‐Fc fusion proteins with picomolar neutralization activity against highly evolved SARS‐CoV‐2 variants

Protein Science, Volume 35, Issue 2, February 2026.
Abstract The rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has compromised the efficacy of many authorized monoclonal antibody products. This highlights the need for alternative strategies, especially for vulnerable populations such as immunocompromised individuals.
Ferran Abancó, Ferran Tarrés‐Freixas, Rosalba Lepore, Elisa Molina‐Molina, Eloi Franco, Rytis Boreika, Edwards Pradenas, Dàlia Raïch‐Regué, Itziar Erkizia, Bonaventura Clotet, Alfonso Valencia, Júlia Vergara‐Alert, Joaquim Segalés, Jorge Carrillo, Nuria Izquierdo‐Useros, Julià Blanco, Benjamin Trinité   +16 more
wiley   +1 more source

A review of the immunogenicity and safety of booster doses of omicron variant-containing mRNA-1273 COVID-19 vaccines in adults and children

Expert Review of Vaccines
Introduction Vaccination against SARS-CoV-2 is an integral pillar of the public health approach to COVID-19. With the emergence of variants of concern that increase transmissibility and escape from vaccine- or infection-induced protection, vaccines have ...
Frances Priddy, Spyros Chalkias, Brandon Essink, Jordan Whatley, Adam Brosz, Ivan T. Lee, Jing Feng, LaRee Tracy, Weiping Deng, Wen Zhou, Honghong Zhou, Avika Dixit, Sabine Schnyder Ghamloush, Bethany Girard, Elizabeth de Windt, Anne Yeakey, Jacqueline Miller, Rituparna Das, Barbara J. Kuter   +18 more
doaj   +1 more source

Time and cost of administering COVID-19 mRNA vaccines in the United States

Human Vaccines & Immunotherapeutics, 2021
In early 2020, the World Health Organization (WHO) declared the coronavirus disease 2019 (COVID-19) outbreak a global pandemic. In response, two novel messenger RNA (mRNA)-based vaccines: mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) were rapidly ...
Benjamin Yarnoff, Steven Bodhaine, Ed Cohen, Philip O. Buck   +3 more
doaj   +1 more source